{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:42:29Z","timestamp":1791985349702,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.pnpbp.2017.10.021","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T20:15:56Z","timestamp":1509480956000},"page":"122-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients"],"prefix":"10.1016","volume":"81","author":[{"given":"Manli","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojia","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinkai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingbo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2017.10.021_bb0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4088\/JCP.v65n0417","article-title":"Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics","volume":"65","author":"Almeras","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0010","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tem.2006.02.005","article-title":"Focus on prolactin as a metabolic hormone","volume":"17","author":"Ben-Jonathan","year":"2006","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/jcp.0b013e31815ac4e5","article-title":"Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives","volume":"27","author":"Byerly","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0020","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1586\/ern.12.137","article-title":"A review of paliperidone palmitate","volume":"12","author":"Chue","year":"2012","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0025","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1038\/npp.2011.94","article-title":"Endogenic and iatrogenic diabetes mellitus in drug-naive schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm","volume":"36","author":"Cohen","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0030","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.nlm.2012.01.008","article-title":"Roles of dopamine D1 and D2 receptors in the acquisition and expression of fat-conditioned flavor preferences in rats","volume":"97","author":"Dela Cruz","year":"2012","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0035","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0040","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","article-title":"Olanzapine - a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses","volume":"53","author":"Fulton","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0045","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1093\/ajcn\/32.8.1734","article-title":"Compressibility of skinfolds and the measurement of subcutaneous fatness","volume":"32","author":"Himes","year":"1979","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0050","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/BF03348932","article-title":"Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance","volume":"16","author":"Hoffmann","year":"1993","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0060","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1176\/appi.ps.55.9.997","article-title":"Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia","volume":"55","author":"Keith","year":"2004","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0065","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1192\/bjp.184.47.s64","article-title":"Diabetes mellitus and schizophrenia: historical perspective","volume":"47","author":"Kohen","year":"2004","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2009.10.022","article-title":"Physical activity and fitness in adolescents at risk for psychosis within the Northern Finland 1986 Birth Cohort","volume":"116","author":"Koivukangas","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0075","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0080","article-title":"Olanzapine versus other atypical antipsychotics for schizophrenia","author":"Komossa","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Kramer","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00210-010-0499-4","article-title":"Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes","volume":"381","author":"Lauressergues","year":"2010","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0095","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1210\/endo-124-3-1558","article-title":"Two forms of glycosylated human prolactin have different pigeon crop sac-stimulating activities","volume":"124","author":"Lewis","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0100","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0105","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","author":"Li","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0110","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol","volume":"160","author":"Lieberman","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0115","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1021\/ac401075u","article-title":"Modified enzyme-linked immunosorbent assay strategy using graphene oxide sheets and gold nanoparticles functionalized with different antibody types","volume":"85","author":"Lin","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0120","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0125","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4088\/JCP.08m04221","article-title":"Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response","volume":"70","author":"Lindenmayer","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/0253-7176.119471","article-title":"Metabolic syndrome in schizophrenia","volume":"35","author":"Malhotra","year":"2013","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0135","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment - insulin resistance and beta-cell function from fasting plasma-glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2014.04.039","article-title":"Cognitive functioning in first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) profile of impairment","volume":"157","author":"McCleery","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0145","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0150","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0899-9007(00)00449-4","article-title":"Hypothalamic dopamine and serotonin in the regulation of food intake","volume":"16","author":"Meguid","year":"2000","journal-title":"Nutrition"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0155","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/schbul\/sbs082","article-title":"Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0160","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders\u2014a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0165","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmet.2011.12.017","article-title":"The Scap\/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals","volume":"15","author":"Moon","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0170","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0447.2006.00982.x","article-title":"The case for long-acting antipsychotic agents in the post-CATIE era","volume":"115","author":"Nasrallah","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0185","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","author":"Pandina","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Perala","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0195","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1176\/ajp.156.4.544","article-title":"Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder","volume":"156","author":"Robinson","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0200","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/schbul\/sbi032","article-title":"Pharmacological treatments for first-episode schizophrenia","volume":"31","author":"Robinson","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0205","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/0026-0495(91)90065-5","article-title":"Understanding \"insulin resistance\": both glucose resistance and insulin resistance are required to model human diabetes","volume":"40","author":"Rudenski","year":"1991","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0210","first-page":"801","article-title":"Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia","volume":"53","author":"Said","year":"2012","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0215","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/ajp.156.1.79","article-title":"Olanzapine versus haloperidol treatment in first-episode psychosis","volume":"156","author":"Sanger","year":"1999","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 16","key":"10.1016\/j.pnpbp.2017.10.021_bb0220","first-page":"14","article-title":"Relapse and rehospitalization: comparing oral and depot antipsychotics","volume":"64","author":"Schooler","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0225","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2147\/PPA.S59371","article-title":"Approaches to improve adherence to pharmacotherapy in patients with schizophrenia","volume":"8","author":"Shuler","year":"2014","journal-title":"Patient Prefer. Adher."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0230","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-244X-14-52","article-title":"Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate","volume":"14","author":"Sliwa","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0235","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S1461145705005110","article-title":"Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients","volume":"8","author":"Smith","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0240","first-page":"107","article-title":"Patient and health care provider perspectives on long acting injectable antipsychotics in schizophrenia and the introduction of olanzapine long-acting injection","volume":"2011","author":"Wehring","year":"2011","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0245","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.09m05284yel","article-title":"A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome","volume":"70","author":"Weiden","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0250","first-page":"841","article-title":"Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review","volume":"10","author":"Xue","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0255","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2017.10.021_bb0260","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1017\/S1461145712001277","article-title":"Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis","volume":"16","author":"Zhang","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617304943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617304943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:16:20Z","timestamp":1659744980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584617304943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":52,"alternative-id":["S0278584617304943"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.10.021","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2017.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}